Or­p­hazyme's pipeline-in-a-prod­uct whiffs in sec­ond tri­al, though FDA de­ci­sion still awaits

Or­p­hazyme’s cen­tral mol­e­cule has whiffed in its sec­ond ma­jor test.

The Dan­ish biotech an­nounced Mon­day that ari­mo­clo­mol, their “pipeline-in-a-prod­uct” mol­e­cule, failed in a Phase III tri­al for in­clu­sion body myosi­tis, a rare mus­cle-wast­ing dis­ease. The drug couldn’t pre­vent dis­ease pro­gres­sion in a 150-per­son study, miss­ing on both pri­ma­ry and sec­ondary end­points.

Or­p­hazyme’s stock $ORPH tum­bled 31% on the news, from $12.39 to $8.50.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER